The structure of human P450 2C9 complexed with flurbiprofen was determined to 2.0 Å by x-ray crystallography. In contrast to other structurally characterized P450 2C enzymes, 2C5, 2C8 and a 2C9 chimera, the native catalytic domain of P450 2C9 differs significantly in the conformation of the helix F to helix G region and exhibits an extra turn at the N-terminus of helix A. In addition, a distinct conformation of the helix B to helix C region allows Arg 108 to hydrogen bond with Asp 293 and Asn 289 on helix I and to interact directly with the carboxylate of flurbiprofen. These interactions position the substrate for regioselective oxidation in a relatively large active site cavity and are likely to account for the high catalytic efficiency exhibited by P450 2C9 for the regioselective oxidation of several anionic non-steroidal antiinflammatory drugs. The structure provides a basis for interpretation of a number of observations regarding the substrate selectivity of P450 2C9 and the observed effects of mutations on catalysis.
INTRODUCTION

P450 2C9
1 is one of three human, microsomal cytochrome P450s (CYP) in subfamily 2C
that contribute extensively to the hepatic metabolism of therapeutic drugs. The P450 2C9 locus is polymorphic leading to a diminished capacity to clear specific drugs in genetically affected individuals. For P450 2C9 substrates, such as warfarin or phenytoin, that have low therapeutic margins of safety, diminished metabolic capacity due to genetic polymorphisms or drug-drug interactions can lead to toxicity at normal therapeutic doses (1) . P450 2C9 has also been implicated in the synthesis of arachidonic acid epoxides in extrahepatic tissues where they regulate blood pressure (2) . Like other P450 subfamilies, the 2C enzymes share roughly 70% or greater amino acid identity. However, the 2C genes have duplicated and diverged rapidly as mammalian species evolved leading to different numbers of enzymes in various species and highly divergent substrate selectivities. This diversity reflects high rates of non-synonymous substitutions that often alter residues that line the active site cavity and determine substrate selectivity.
Human P450s 2C9 and 2C19 are closely related with roughly 91% amino acid identity.
Although they exhibit distinct substrate selectivities, residues predicted to line the active site cavity, based on the published structures of other mammalian P450s (3-6), do not differ between the two enzymes. This suggests that conformation changes are likely to underlie differences in the substrate selectivities of P450s 2C9 and 2C19 and that the structure(s) of one or both will differ from those previously published. This is supported by studies of chimeric enzymes generated from P450s 2C9 and 2C19 that have generally identified amino acid residues that are predicted to reside outside the substrate-binding cavity as determinants of their distinct catalytic properties (7) (8) (9) .
by guest on http://www.jbc.org/ Downloaded from 5 P450 2C9 exhibits a selectivity for the oxidation of relatively small, lipophilic anions such as the non-steroidal anti-inflammatory drugs, flurbiprofen, ibuprofen, naproxen and diclofenac as well as the hypolipidemic agent, gemfibrozil. It has been hypothesized that a basic residue in the active site of P450 2C9 stabilizes the binding of these anionic substrates (10-13).
However, the structure (PDB:1OG5) of a chimeric form of P450 2C9 published earlier did not provide evidence for a basic residue that would serve this role. The relatively large size of the active site exhibited by the 1OG5 structure rendered the selectivity of P450 2C9 for small lipophilic anions particularly difficult to understand.
Our objective in determining the structure of P450 2C9 was to preserve the native sequence of the enzyme to the greatest extent possible and to co-crystallize the enzyme with a representative anionic substrate bound in the active site in order to identify structural determinants underlying the substrate selectivity of the enzyme for anionic non-steroidal antiflammatory drugs. Eukaryotic P450s are monotopic membrane proteins with the microsomal P450s having a single transmembrane helix at the N-terminus that is not found in mitochondrial P450s. Removal of the N-terminal transmembrane domain has facilitated structure determination of the catalytic domains of microsomal P450s (14) . However, when expressed in Escherichia coli without their N-terminal transmembrane helices, microsomal
P450s generally retain a capacity to bind to membranes (15) . In the case of P450 2C5 and the related enzyme P450 2C3, high ionic strength buffers reversed membrane binding (15, 16) . A second modification is generally used that extends the C-terminus of the enzyme to include a 4-residue histidine tag to facilitate purification of the truncated enzymes. P450 2C9 was modified similarly for crystallization in the present study, and the catalytically active construct is designated P450 2C9dH. In contrast to the modified P450 2C9 employed to determine the 1OG5 6 structure (4), no additional mutations were introduced within the catalytic domain of the protein for the present study. I224L that correspond to residues in CYP2C5/3LVdH, and the structure with or without warfarin bound is more similar to that CYP2C5/3LVdH in this region than the 1R9O structure reported here. In addition, warfarin was bound to the 1OG5 enzyme in the distal end of the active site cavity with the site of hydroxylation residing in an unproductive position more than 10Å from the site of oxygen binding, which could reflect the presence of an unidentified substance bound near the iron in the substrate binding site (4) . In contrast, the 1R9O structure indicates that flurbiprofen is positioned with the site of hydroxylation located for oxidative attack by the reactive, hypervalent iron-oxo intermediate derived from reduction of molecular oxygen by the enzyme. The 1R9O structure described in this manuscript also identifies an important role for Arg 108 in stabilizing the binding of flurbiprofen and reveals a distinctly different conformation of the helix B to helix C region where Arg 108 resides. The 1R9O structure contributes significantly to the interpretation of previous mutagenesis studies implicating R108 (17, 18) , N289 (7-9) and D293 (19) in substrate recognition and provides a basis for understanding the selectivity exhibited by 2C9 for anionic substrates.
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METHODS
2C9
Construct. The pCW2C9dH construct was prepared by ligating two fragments bearing portions of the CYP2C9 cDNA into a vector derived from the pCW2C5/3LVdH plasmid by digestion with the Sac1 and Sal1 restriction enzymes. A Sac1-Sph1 fragment encoding the Nterminal portion of CYP2C9 beginning with codon 23 was excised from the pCW2C9 plasmid described earlier for expression of the full length enzyme in E. coli (20) . The portion encoding the C-terminus was PCR amplified from the plasmid using a lower primer employed previously to incorporate a 4 residue histidine tag at the C-terminus of CYP2C5 (16) leading to an alteration of the C-terminal residue of CYP2C9 to a valine plus the histidine tag. The PCR fragment was digested with the restriction endonucleases, Sph1 and Sal1, and the three fragments were ligated together to create the expression vector. This strategy fused the coding sequence of 2C9
beginning at residue 23 with the first 5 residues, MAKKT, of the modified N-terminus used to express P450 2C5 for crystallization, and replaced the C-terminal valine with an isoleucine plus a four histidine tag to facilitate purification (Fig. 1 ).
Protein Expression and Purification. P450 2C9dH was expressed and purified as previously described for 2C5dH with several modifications (14) . Three liters of Terrific Broth were seeded with 6 ml of an overnight culture of XL-1 blue E. coli containing the pCW2C9dH plasmid. Following the addition of 240 mg of δ-aminolevulinic acid and 720 mg of isopropyl-β-D-thiogalactoside, the culture was incubated at 30º C for 48 hrs with shaking at 225 RPM. Cells were harvested by centrifugation and resuspended in 10% of the original culture volume of 20 mM KPi, 20% glycerol, 1 mM phenylmethanesulfonyl fluoride, and 10 mM β-mercaptoethanol.
Lysozyme (0.3 mg/ml) was added and the cells were incubated with stirring for 45 minutes at 4º
C. An equal volume of cold water was added and the incubation continued with stirring for an 8 additional 15 min. The spheroplasts were pelleted by centrifugation at 7,000 x g for 10 min, the supernatant discarded and pellets frozen in liquid nitrogen and stored at -80º C overnight. The pellet was thawed, resuspended in 500 mM KPi, pH 7.4, 20% glycerol, 0.5 mM phenylmethanesulfonyl fluoride, 10 mM β-mercaptoethanol and sonicated for 3 x 45 second pulses with 1 minute cooling on ice between the pulses. Following clarification by centrifugation at 7000 x g for 10 min at 4º C, CYMAL-5 detergent (Anatrace, Maumee, OH) was added to a final concentration of 4.8 mM, and the material was incubated with stirring at 4 o C for 30minutes. Following this incubation, the material was centrifuged at 100,000 x g for 60min at 4º C. The supernatant was incubated with 6 ml of NiNTA resin (Qiagen.Valencia, CA) that was pre-equilibrated with 150 ml of 500 mM KPi, pH 7.4, and 20% glycerol. After 3 hr, the resin was collected by gentle centrifugation. The resin was washed with 40 ml of 500 mM KPi, pH Diclofenac Hydroxylation. P450s 2C9 and 2C9dH (10 pmol) were reconstituted with purified rabbit liver P450 reductase as described previously for P450 2C5dH (15) . Reactions were carried out in 1ml incubations containing 50mM HEPES, pH 7.4, 0.1mM diclofenac, and 1mM NADPH. Following a 30 min incubation, the reaction was terminated by the addition of 0.2 ml of 1N HCl and placed on ice. The products and substrate were extracted from the reaction mixture and analyzed by reverse-phase chromatography as described (21) . Elution was monitored by UV absorption at 280 nm, and the integrated elution profiles were compared to those produced by known amounts 4-hydroxy-diclofenac (BD Biosciences, Bedford, MA) prepared in the same manner.
Flurbiprofen Binding Studies. The conversion of P450 2C9dH from a low spin to a high spin state in the presence of flurbiprofen was monitored spectrophotometrically as described (22) . Purified protein was diluted to 1.9 µM in 50 mM KPi, pH 7.4, containing 500 mM NaCl, 20% glycerol, 1mM EDTA, and 02.mM DTT in a 1 cm pathlength microcuvette. Aliquots of diclofenac dissolved in ethanol were added to the solution, and the differences in the absorption between 394 nm and 418 nm were recorded. The apparent binding constant was estimated as described previously (8) .
Mass Spectral Analysis. Several large crystals were harvested and dissolved in 50 mM KPi, pH 7.4, 500 mM NaCl, 20% glycerol, 1 mM EDTA, and 0.2 mM DTT. The samples were (23) were used to process the data, and the statistical analysis is presented in Table 1 .
The structure of 2C9 was solved with the 2.3 Å 2C5/3LVdH structure (PDB:1NR6) as a search model for molecular replacement. Multiple cycles of editing and adjustment of the model into σ A -weighted 2|Fo|-|Fc| composite omit and |Fo|-|Fc| electron density maps were performed using the programs XFIT/XTALVIEW (24) and O (25) . The models were refined against the 2.0 Å data using conjugate gradient least squares minimization, simulated annealing and isotropic individual B-factor refinement using the program CNS (26) . During the final stages of refinement, water molecules were added, and flurbiprofen was modeled into the 2|Fo|-|Fc| 
RESULTS AND DISCUSSION
The 2C9dH construct was designed to express residues 23-489 of the catalytic domain for crystallization without internal modifications that might affect the structure. The first 22 amino acid residues that include the transmembrane, signal anchor domain were replaced with the sequence MAKKT, Fig. 1 . This sequence was derived from the first 5 residues of the modified N-terminus that had been optimized for the expression and crystallization of rabbit P450 2C5 (16) . The construct used here differs from that used by Williams et al. (4) to determine the 1OG5 and 1OG2 structures of CYP2C9 with and without S-warfarin to 2.55 Å and 2.66 Å, respectively. As shown in Fig. 1 , the constructs used for the 1OG5 and 1OG2 structures incorporated several internal substitutions as well as differences in the N-and C-terminal sequences. Residue numbering for the constructs corresponds to that of the wild-type, P450 2C9
sequence throughout the text.
The 1R9O construct described here expresses to greater than 400nmol/L in E. coli based on whole cell CO reduced difference spectrum and can be extensively purified with only minor modifications to protocols in use for 2C5/3LVdH (14) . P450 2C9dH is active when reconstituted with P450 reductase, catalyzing the 4'-hydroxylation of diclofenac, with a kcat value of 11.8 nmol/min/nmol P450 compared to 14.1 nmol/min/nmol P450 for the full-length enzyme. Flurbiprofen binds to P450 2C9dH with an apparent binding constant of 9.6 µM determined by monitoring the partial conversion of the enzyme to the high spin ferric form.
This value compares closely to a value of 14.1 µM reported for the wild-type enzyme (30).
These results suggest that the modifications to the N-and C-termini do not significantly affect flurbiprofen binding or P450 2C9 oxidation of diclofenac.
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Data from a single crystal that diffracted to 2.0 Å in space group R3 with a single molecule in the asymmetric unit was used for model building and refinement. Molecular replacement based on the structure of 2C5 (PDB: 1NR6) was used for initial phasing and as a basis for building the protein model. Subsequent refinement and fitting resulted in a structure with an R value of 0.19 and an Rfree of 0.24 ( Table 1 ). The electron density maps did not define several residues sufficiently for modeling. These include the 7 N-terminal residues of the truncated protein preceding residue 26, residues 38-42 between the proline rich motif and helix A, residues 214-220 between helices F and G and the last 2 residues of the C-terminal His-tag ( Fig. 1) . Matrix assisted laser desorption ionization/time-of-flight spectrometry following recovery of the crystallized protein indicated an atomic mass of 54160 (predicted 54151)
confirming that the crystallized protein had not been cleaved. Additionally, the final model included one glycerol and 255 H 2 O molecules ( Table 1 ). The 2|Fo|-|Fc| electron density maps contoured at 1.0 σ clearly defined the position and orientation of flurbiprofen in the active site, which was modeled as S-flurbiprofen based on electron density defining this diastereomer. The experimentally determined structure of 2C9dH displays good stereochemistry with only 1.6% of the residues found in generously allowed or disallowed regions of the Ramachandran plot ( Table   1 ).
The 1R9O structure of the flurbiprofen complex of 2C9dH corresponds closely to the 1OG5 structure in many regions with an rms deviation of 0.74Å. However, significant differences are seen in the N-terminus preceding residue 53 in helix A, residues 97-121 between helices B and C, residues 197-232 encompassing helix F through the beginning of helix G, and residues 467-478 that form the turn in the C-terminal, anti-parallel β-sheet, Fig. 1 . These differences are clustered in one quadrant of the structure, Fig. 2 , which also contains regions that Helix G' is not evident in the 1R9O structure. The corresponding region forms an extended structure with attendant shifts in the conformation of residues that would correspond to helix A' and F'. In this regard, it is important to note that the sequence of the 1OG5 sequence differs from the native enzyme in the helix G' region, Fig. 1 . The substitutions introduced into the helix F-G region of the 1OG5 construct correspond to the sequence of the 2C5 construct crystallized in earlier studies from our laboratory (15) . Most notably, the S220P and P221A mutations in 1OG5 move Pro 221 to a position seen for Pro 220 in 2C8 and 2C5, where it forms a tight turn between helices F' and G'. The repositioning of the proline may stabilize the helix F'-G' region of P450 2C9 in a conformation similar to that seen in P450's 2C8 and 2C5. In addition, the P221A, L222I, and L223I substitutions could increase the propensity of this region to form helical structures. The distinct conformation of the helix G' region exhibited by the native sequence in the 1R9O structure is consistent with previous studies of chimeric enzymes constructed from 2C9 and 2C19, which have highly similar amino acid sequences. Analysis of chimeras indicated that the S220P and P221S differences between the two enzymes contributes to the distinct selectivity of 2C19 for the substrates, omeprazole (32) and S-mephenytoin (7).
However, it is not necessary to introduce the reverse mutations into 2C19 to confer diclofenac hydroxylation (9) or sulfaphenazole binding (8) (5) and 2B4 (31) and can adopt alternative conformations without greatly altering the secondary structure immediately before and after due to the presence of glycine residues that flank residues 97 and 110, Fig. 1 . These GXG motifs flanking the flexible region can serve as swivel points for the encompassed segment, which allow localized conformation changes without significantly perturbing other portions of the structure.
Hydrogen bonding of R108 with two residues on helix I, D293 and T289, stabilizes the observed conformation of R108 in the active site, Fig. 3 . This result indicates that R108 is likely to be critical for the relatively high affinity of flurbiprofen binding to 2C9. Substitution of other amino acids for R108 have been shown to alter flurbiprofen binding (18) and to greatly diminish the oxidation of S-warfarin (18) and diclofenac (17, 18) . Interestingly, hydroxylation of pyrene, a neutral substrate that is not capable of hydrogen bonding with R108, was largely unaffected by the R108F substitution (18) . Mutagenesis of D293 (18, 19) also profoundly affects the oxidation of diclofenac, another anionic substrate, by 2C9. However, this mutation also affects the stability of the enzyme (18) . D293 exhibits hydrogen bonding interactions that are likely to stabilize the structurally adjacent turn formed by the polypeptide backbone at residues 111-114, [1] 99.8(100) <I/σ I > [1] 7.4 (1.1) R symm (I) [1] 0.08 (0.41) Refinement R-factor 0.19 R free (5% of data) 0.24 rms deviation bonds (Å) 0.05 rms deviation angles (deg) [2] 2.68 Model Residues / No. of atoms /Ave B-factor (Å 2 ) Protein [3] 
